Ethismos is entering a major phase 2 program evaluating amitifadine as an adjunct to (prescribed in addition to) opioids to reduce risk of opioid use disorder and overdose associated with opioids used to treat chronic pain.


The Ethismos therapy is one of the few advanced development programs focused on prevention—before the patient has developed opioid use disorder—rather than the more difficult to treat situation after the patient has developed the addiction to opioids. 

This clinical trial program is being designed and executed in collaboration with some of the most prominent and highly-regarded scientists and clinicians from several prestigious institutions including Massachusetts General Hospital, Brigham and Women’s Hospital, Montefiore Medical Center, and the University of Washington.